DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the details of six presentations on the Company’s acellular tissue engineered vessel (ATEV™) that are scheduled for the 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques And Horizons (VEITHsymposium), to be held November 18-22, 2025 in New York, NY. The VEITHsymposium is a premier educational event for vascular surgeons, interventional radiologists, interventional cardiologists, and other vascular specialists.